Now within reach.
Aiming to reach a billion patients worldwide with affordable, lifesaving medicines.
the COVID-19 outbreak
DCGI gives NOD for Restricted Emergency Use of Itolizumab in Moderate to Severe COVID-19 Patients.
saves lives. We are accelerating drug innovation and development for companies globally.
Meeting unmet patient needs.
Our novel biologics address unmet medical needs across the world.
The 10-cent answer to Diabetes.
At 10 cents a day our insulin
is a game changer in the developing world.
WHO WE ARE
Driven by purpose.
We are a global biopharmaceutical company with the belief that everyone, everywhere deserves access to affordable quality medicines.